Rymo Technologies Raises Rs 10 Cr in Seed Round Led by IAN Group

Why It Matters

The funding accelerates scaling of affordable, data‑driven rehab technology, addressing therapist shortages and rising stroke incidence in emerging markets. It also underscores growing investor confidence in Indian med‑tech innovation.

Key Takeaways

• Rs 10 cr seed round led by IAN Group.
• Funds target product R&D, manufacturing, Indian and overseas expansion.
• 452 devices installed across 354 clinical customers.
• AI‑driven Mobi‑L shows 25% faster patient recovery.
• Addresses therapist shortage and high rehab costs in emerging markets.

Pulse Analysis

The global burden of stroke and neurological disorders is climbing, with the World Health Organization estimating over 15 million new cases each year. In many emerging economies, patients face a double challenge: a scarcity of trained rehabilitation therapists and the prohibitive price of existing robotic rehab platforms. This gap has spurred a wave of med‑tech startups seeking to democratize neuro‑rehabilitation through lower‑cost, technology‑driven solutions. Investors are increasingly viewing this niche as both a social imperative and a high‑growth market, especially as aging populations expand the demand for efficient recovery pathways.

Rymo Technologies tackles that unmet need with its flagship Mobi‑L system, a multi‑joint robotic exoskeleton that blends artificial intelligence, virtual reality and modular hardware. The platform’s proprietary algorithms analyze patient data in real time, customizing therapy intensity and tracking progress against measurable outcomes. To date, the company has deployed more than 452 units across 354 clinical customers, including AIIMS and Apollo Hospitals, and has delivered over 15 000 therapy hours to 7 500 patients. Clinical studies cited by Rymo claim up to a 25 percent acceleration in recovery speed, positioning the device as a cost‑effective alternative to traditional therapist‑led programs.

The recent Rs 10 crore seed round, led by IAN Group’s evergreen fund, provides Rymo with the runway to scale manufacturing, deepen AI research and expand into ASEAN and Middle‑East markets. By localising production and forging distribution partnerships, the startup can lower unit costs and reach hospitals that previously could not afford robotic therapy. This infusion of capital also signals growing confidence among Indian investors in home‑grown med‑tech ventures, potentially catalysing a broader ecosystem of innovation in digital health. If Rymo sustains its clinical momentum, it could set a new benchmark for affordable, data‑driven neuro‑rehabilitation worldwide.

Deal Summary

Robotic neuro‑rehabilitation startup Rymo Technologies secured Rs 10 crore in a seed funding round led by IAN Group’s evergreen fund, with participation from angel investors. The capital will accelerate product innovation, expand manufacturing, and support international expansion.